GLIOMA, MALIGNANT

This early-stage study is testing a drug called niraparib for two types of aggressive brain cancer. It first checks if the drug reaches the tumor effectively after a short pre-surgery dose. If it does, participants can continue taking the drug, sometimes with radiation, to try to…

This early-stage study is testing the safety of a personalized cancer vaccine for adults with a newly diagnosed, aggressive brain tumor called glioblastoma. The vaccine is designed to train the patient's immune system to attack the tumor. Researchers will give the vaccine to a sm…

This early-stage trial is testing a new drug called AZD1390 in combination with standard radiation therapy for adults with aggressive brain tumors (grade 4 glioma or glioblastoma). The study first checks if the drug successfully reaches the tumor tissue. Patients whose tumors sho…

This study aims to understand how aggressive brain tumors (gliomas) suppress the body's immune system. Researchers will use special MRI and PET scans on 31 adult patients to look for specific signs of immune suppression within the tumor. The goal is to gather knowledge about the …

This early study aims to understand if an experimental drug called niraparib reaches brain tumor tissue effectively. It involves 16 adults with recurrent, slow-growing brain tumors (gliomas) who are already scheduled for surgery. Researchers will measure how much of the drug gets…